Impact News +++ Corporate News: pferdewetten.de AG (EQS) +++ PFERDEWETTEN.DE Aktie -3,38%

ESPERION Aktie

>ESPERION Aktienkurs

0.907 EUR -2.0% (Tradegate)

Ask: 0.8944 EUR / 11180 Stück

Bid: 0.8688 EUR / 11510 Stück

Tagesumsatz: 5900 Stück

Realtime Kurs von 8 bis 22 Uhr!

ESPERION Aktie über LYNX handeln

Intraday

1 Jahr

>ESPERION Performance

1 Woche: -4,9%

1 Monat: +29,3%

3 Monate: -43,9%

6 Monate: -57,6%

1 Jahr: -56,2%

laufendes Jahr: -58,9%

>ESPERION Aktie

Name:

ESPERION THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US29664W1053 / A1W1SJ

Symbol/ Ticker:

0ET (Frankfurt) / ESPR (NASDAQ)

Kürzel:

FRA:0ET, ETR:0ET, 0ET:GR, NASDAQ:ESPR

Index:

Webseite:

https://www.esperion.com/

Marktkapitalisierung:

199.93 Mio. EUR

Umsatz:

223.51 Mio. EUR

EBITDA:

-34.37 Mio. EUR

Gewinn je Aktie:

-0.629 EUR

Schulden:

511.49 Mio. EUR

Liquide Mittel:

98.71 Mio. EUR

Umsatz-/ Gewinnwachstum:

-52.8% / -

KGV/ KGV lG:

- / 1.19

KUV/ KBV/ PEG:

0.84 / 86.74 / -

Gewinnm./ Eigenkapitalr.:

-59.03% / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 49.522 USD.

Suchwörter:

ESPERION

Letzte Datenerhebung:

25.06.25

>ESPERION Eigentümer

Aktien: 198.2 Mio. St.

f.h. Aktien: 196.42 Mio. St.

Insider Eigner: 0.58%

Instit. Eigner: 59.3%

Leerverk. Aktien: 13.37%

>ESPERION Peer Group

AMNEAL

CASSAVA SCIENCES

CHEMED

EISAI ADR

HUTCHMED ADR

INSPIRE MEDICAL

NEURONETICS

PENUMBRA

SONOVA ADR

STANDARD BIOTOOLS

>ESPERION Chart & Kurs - NASDAQ

>ESPERION News

19.06.25 - 07:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Esperion Therapeutics im Wert von 8328 USD (Insiderkauf)
	Halladay, Benjamin - Vorstand - Tag der Transaktion: 2025-06-17...

19.06.25 - 07:01	Insiderhandel: President and CEO verkauft Aktien von Esperion Therapeutics im Wert von 33796 USD (Insiderkauf)
	Koenig, Sheldon L. - Vorstand - Tag der Transaktion: 2025-06-17...

19.06.25 - 07:01	Insiderhandel: General Counsel verkauft Aktien von Esperion Therapeutics im Wert von 7398 USD (Insiderkauf)
	Looker, Benjamin - Vorstand - Tag der Transaktion: 2025-06-17...

12.05.25 - 14:06

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire EN)

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur....

09.05.25 - 14:03	Esperion to Participate in H.C. Wainwright′s 3rd Annual BioConnect Investor Conference (GlobeNewswire EN)
	ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET....

08.05.25 - 22:33	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
	ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan....

08.05.25 - 12:33	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada (GlobeNewswire EN)
	– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales –...

07.05.25 - 19:45	ESPR′s Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
	Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls....

06.05.25 - 14:30	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
	Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -16.67% and 12.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

06.05.25 - 12:09	Esperion Therapeutics GAAP EPS of -$0.21 misses by $0.06, revenue of $64.99M beats by $10.8M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 12:03	Esperion Reports First Quarter 2025 Financial Results (GlobeNewswire EN)
	– Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y –...

29.04.25 - 17:30	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

25.04.25 - 14:03	Esperion to Participate in The Citizens Life Sciences Conference (GlobeNewswire EN)
	ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET....

24.04.25 - 14:03	Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 (GlobeNewswire EN)
	– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC –...

22.04.25 - 03:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Esperion Therapeutics im Wert von 8 USD (Insiderkauf)
	Halladay, Benjamin - Vorstand - Tag der Transaktion: 2025-04-17...

22.04.25 - 03:01	Insiderhandel: Chief Commercial Officer verkauft Aktien von Esperion Therapeutics im Wert von 106 USD (Insiderkauf)
	Warren, Eric - Vorstand - Tag der Transaktion: 2025-04-17...

10.04.25 - 14:03	Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 (GlobeNewswire EN)
	Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases...

03.04.25 - 19:00	Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? (Zacks)
	Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

21.03.25 - 15:45	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
	Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia....

20.03.25 - 13:03	Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia (GlobeNewswire EN)
	– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia –...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram